Financhill
Sell
20

XAIR Quote, Financials, Valuation and Earnings

Last price:
$0.20
Seasonality move :
0.88%
Day range:
$0.20 - $0.21
52-week range:
$0.19 - $1.49
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.75x
P/B ratio:
1.04x
Volume:
1.7M
Avg. volume:
2.4M
1-year change:
-84%
Market cap:
$18.4M
Revenue:
$1.2M
EPS (TTM):
-$1.06

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
XAIR
Beyond Air
$1.4M -- 195.4% -- $2.25
IVF
INVO Fertility
$1.6M -- -8.8% -- --
NMTC
NeuroOne Medical Technologies
$1.3M -- 157.41% -57.14% $1.45
NTRB
Nutriband
$665K -$0.13 59.2% -38.1% $13.00
NVNO
enVVeno Medical
-- -$0.34 -- -26.67% $16.50
SINT
SINTX Technologies
$725K -$0.71 20.07% -96.14% $30.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
XAIR
Beyond Air
$0.21 $2.25 $18.4M -- $0.00 0% 3.75x
IVF
INVO Fertility
$2.33 -- $1.6M -- $0.00 0% 0.12x
NMTC
NeuroOne Medical Technologies
$0.64 $1.45 $19.7M -- $0.00 0% 3.16x
NTRB
Nutriband
$6.41 $13.00 $71.5M -- $0.00 0% 31.78x
NVNO
enVVeno Medical
$3.57 $16.50 $62.6M -- $0.00 0% 348.27x
SINT
SINTX Technologies
$2.71 $30.00 $6.8M -- $0.00 0% 1.69x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
XAIR
Beyond Air
0.34% -0.284 0.22% 2.15x
IVF
INVO Fertility
-- 3.433 -- --
NMTC
NeuroOne Medical Technologies
-- -0.602 -- 2.23x
NTRB
Nutriband
1.68% 3.138 0.28% 4.65x
NVNO
enVVeno Medical
-- 0.246 -- --
SINT
SINTX Technologies
0.82% 0.321 0.68% 1.91x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
XAIR
Beyond Air
-$215K -$11M -151.32% -225.36% -1192.54% -$8.3M
IVF
INVO Fertility
-- -- -- -- -- --
NMTC
NeuroOne Medical Technologies
$1.9M $1.7M -238.93% -238.93% 64.45% $183.6K
NTRB
Nutriband
$191K -$1.4M -65.19% -69.58% -210.38% -$1.1M
NVNO
enVVeno Medical
-- -$5M -- -- -- -$4M
SINT
SINTX Technologies
$38K -$1.6M -146.19% -148.9% -875.52% -$1.3M

Beyond Air vs. Competitors

  • Which has Higher Returns XAIR or IVF?

    INVO Fertility has a net margin of -1215.67% compared to Beyond Air's net margin of --. Beyond Air's return on equity of -225.36% beat INVO Fertility's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    XAIR
    Beyond Air
    -20.06% -$0.15 $18.4M
    IVF
    INVO Fertility
    -- -- --
  • What do Analysts Say About XAIR or IVF?

    Beyond Air has a consensus price target of $2.25, signalling upside risk potential of 981.73%. On the other hand INVO Fertility has an analysts' consensus of -- which suggests that it could grow by 157.51%. Given that Beyond Air has higher upside potential than INVO Fertility, analysts believe Beyond Air is more attractive than INVO Fertility.

    Company Buy Ratings Hold Ratings Sell Ratings
    XAIR
    Beyond Air
    1 1 0
    IVF
    INVO Fertility
    0 0 0
  • Is XAIR or IVF More Risky?

    Beyond Air has a beta of 0.250, which suggesting that the stock is 75.019% less volatile than S&P 500. In comparison INVO Fertility has a beta of 2.243, suggesting its more volatile than the S&P 500 by 124.267%.

  • Which is a Better Dividend Stock XAIR or IVF?

    Beyond Air has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INVO Fertility offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beyond Air pays -- of its earnings as a dividend. INVO Fertility pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XAIR or IVF?

    Beyond Air quarterly revenues are $1.1M, which are larger than INVO Fertility quarterly revenues of --. Beyond Air's net income of -$13M is higher than INVO Fertility's net income of --. Notably, Beyond Air's price-to-earnings ratio is -- while INVO Fertility's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beyond Air is 3.75x versus 0.12x for INVO Fertility. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XAIR
    Beyond Air
    3.75x -- $1.1M -$13M
    IVF
    INVO Fertility
    0.12x -- -- --
  • Which has Higher Returns XAIR or NMTC?

    NeuroOne Medical Technologies has a net margin of -1215.67% compared to Beyond Air's net margin of 54.53%. Beyond Air's return on equity of -225.36% beat NeuroOne Medical Technologies's return on equity of -238.93%.

    Company Gross Margin Earnings Per Share Invested Capital
    XAIR
    Beyond Air
    -20.06% -$0.15 $18.4M
    NMTC
    NeuroOne Medical Technologies
    58.85% $0.06 $2.9M
  • What do Analysts Say About XAIR or NMTC?

    Beyond Air has a consensus price target of $2.25, signalling upside risk potential of 981.73%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of $1.45 which suggests that it could grow by 127.49%. Given that Beyond Air has higher upside potential than NeuroOne Medical Technologies, analysts believe Beyond Air is more attractive than NeuroOne Medical Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    XAIR
    Beyond Air
    1 1 0
    NMTC
    NeuroOne Medical Technologies
    1 0 0
  • Is XAIR or NMTC More Risky?

    Beyond Air has a beta of 0.250, which suggesting that the stock is 75.019% less volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.671%.

  • Which is a Better Dividend Stock XAIR or NMTC?

    Beyond Air has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beyond Air pays -- of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XAIR or NMTC?

    Beyond Air quarterly revenues are $1.1M, which are smaller than NeuroOne Medical Technologies quarterly revenues of $3.3M. Beyond Air's net income of -$13M is lower than NeuroOne Medical Technologies's net income of $1.8M. Notably, Beyond Air's price-to-earnings ratio is -- while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beyond Air is 3.75x versus 3.16x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XAIR
    Beyond Air
    3.75x -- $1.1M -$13M
    NMTC
    NeuroOne Medical Technologies
    3.16x -- $3.3M $1.8M
  • Which has Higher Returns XAIR or NTRB?

    Nutriband has a net margin of -1215.67% compared to Beyond Air's net margin of -211%. Beyond Air's return on equity of -225.36% beat Nutriband's return on equity of -69.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    XAIR
    Beyond Air
    -20.06% -$0.15 $18.4M
    NTRB
    Nutriband
    29.58% -$0.12 $11.4M
  • What do Analysts Say About XAIR or NTRB?

    Beyond Air has a consensus price target of $2.25, signalling upside risk potential of 981.73%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 102.81%. Given that Beyond Air has higher upside potential than Nutriband, analysts believe Beyond Air is more attractive than Nutriband.

    Company Buy Ratings Hold Ratings Sell Ratings
    XAIR
    Beyond Air
    1 1 0
    NTRB
    Nutriband
    1 0 0
  • Is XAIR or NTRB More Risky?

    Beyond Air has a beta of 0.250, which suggesting that the stock is 75.019% less volatile than S&P 500. In comparison Nutriband has a beta of 1.185, suggesting its more volatile than the S&P 500 by 18.545%.

  • Which is a Better Dividend Stock XAIR or NTRB?

    Beyond Air has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beyond Air pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XAIR or NTRB?

    Beyond Air quarterly revenues are $1.1M, which are larger than Nutriband quarterly revenues of $645.8K. Beyond Air's net income of -$13M is lower than Nutriband's net income of -$1.4M. Notably, Beyond Air's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beyond Air is 3.75x versus 31.78x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XAIR
    Beyond Air
    3.75x -- $1.1M -$13M
    NTRB
    Nutriband
    31.78x -- $645.8K -$1.4M
  • Which has Higher Returns XAIR or NVNO?

    enVVeno Medical has a net margin of -1215.67% compared to Beyond Air's net margin of --. Beyond Air's return on equity of -225.36% beat enVVeno Medical's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    XAIR
    Beyond Air
    -20.06% -$0.15 $18.4M
    NVNO
    enVVeno Medical
    -- -$0.22 --
  • What do Analysts Say About XAIR or NVNO?

    Beyond Air has a consensus price target of $2.25, signalling upside risk potential of 981.73%. On the other hand enVVeno Medical has an analysts' consensus of $16.50 which suggests that it could grow by 362.19%. Given that Beyond Air has higher upside potential than enVVeno Medical, analysts believe Beyond Air is more attractive than enVVeno Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    XAIR
    Beyond Air
    1 1 0
    NVNO
    enVVeno Medical
    1 0 0
  • Is XAIR or NVNO More Risky?

    Beyond Air has a beta of 0.250, which suggesting that the stock is 75.019% less volatile than S&P 500. In comparison enVVeno Medical has a beta of 0.803, suggesting its less volatile than the S&P 500 by 19.726%.

  • Which is a Better Dividend Stock XAIR or NVNO?

    Beyond Air has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beyond Air pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XAIR or NVNO?

    Beyond Air quarterly revenues are $1.1M, which are larger than enVVeno Medical quarterly revenues of --. Beyond Air's net income of -$13M is lower than enVVeno Medical's net income of -$4.5M. Notably, Beyond Air's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beyond Air is 3.75x versus 348.27x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XAIR
    Beyond Air
    3.75x -- $1.1M -$13M
    NVNO
    enVVeno Medical
    348.27x -- -- -$4.5M
  • Which has Higher Returns XAIR or SINT?

    SINTX Technologies has a net margin of -1215.67% compared to Beyond Air's net margin of -882.81%. Beyond Air's return on equity of -225.36% beat SINTX Technologies's return on equity of -148.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    XAIR
    Beyond Air
    -20.06% -$0.15 $18.4M
    SINT
    SINTX Technologies
    19.79% -$1.26 $3.9M
  • What do Analysts Say About XAIR or SINT?

    Beyond Air has a consensus price target of $2.25, signalling upside risk potential of 981.73%. On the other hand SINTX Technologies has an analysts' consensus of $30.00 which suggests that it could grow by 1007.01%. Given that SINTX Technologies has higher upside potential than Beyond Air, analysts believe SINTX Technologies is more attractive than Beyond Air.

    Company Buy Ratings Hold Ratings Sell Ratings
    XAIR
    Beyond Air
    1 1 0
    SINT
    SINTX Technologies
    1 1 0
  • Is XAIR or SINT More Risky?

    Beyond Air has a beta of 0.250, which suggesting that the stock is 75.019% less volatile than S&P 500. In comparison SINTX Technologies has a beta of 0.821, suggesting its less volatile than the S&P 500 by 17.937%.

  • Which is a Better Dividend Stock XAIR or SINT?

    Beyond Air has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beyond Air pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XAIR or SINT?

    Beyond Air quarterly revenues are $1.1M, which are larger than SINTX Technologies quarterly revenues of $192K. Beyond Air's net income of -$13M is lower than SINTX Technologies's net income of -$1.7M. Notably, Beyond Air's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beyond Air is 3.75x versus 1.69x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XAIR
    Beyond Air
    3.75x -- $1.1M -$13M
    SINT
    SINTX Technologies
    1.69x -- $192K -$1.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Berkshire The Best Stock to Buy in a Bad Market?
Is Berkshire The Best Stock to Buy in a Bad Market?

Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…

Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?

The big picture trends in e‑commerce sales are clearly in…

Is RTX The Best Growth Stock?
Is RTX The Best Growth Stock?

Among the worldwide aerospace and defense markets, the US controls…

Stock Ideas

Buy
71
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Buy
60
RGC alert for May 6

Regencell Bioscience Holdings [RGC] is up 73.72% over the past day.

Buy
63
SKX alert for May 6

Skechers USA [SKX] is down 0.07% over the past day.

Sell
20
PTCT alert for May 6

PTC Therapeutics [PTCT] is down 11% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock